Spots Global Cancer Trial Database for stage 0 chronic lymphocytic leukemia
Every month we try and update this database with for stage 0 chronic lymphocytic leukemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Alemtuzumab and Rituximab in Treating Patients With High-Risk, Early-Stage Chronic Lymphocytic Leukemia | NCT00436904 | Leukemia | Alemtuzumab Rituximab | 18 Years - | Mayo Clinic | |
| FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia | NCT00769522 | Chronic Lymphoc... | Rituximab Bendamustine Cyclophosphamid... Fludarabine | 18 Years - | German CLL Study Group | |
| Rituximab, Fludarabine, and Cyclophosphamide or Observation Alone in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia | NCT00275054 | Chronic Lymphoc... | Fludarabine Cyclophosphamid... Rituximab | 18 Years - | German CLL Study Group | |
| Alemtuzumab and Rituximab in Treating Patients With High-Risk, Early-Stage Chronic Lymphocytic Leukemia | NCT00436904 | Leukemia | Alemtuzumab Rituximab | 18 Years - | Mayo Clinic | |
| Combination Chemotherapy, Total-Body Irradiation, and Alemtuzumab in Treating Patients Undergoing an Autologous Stem Cell Transplant for Stage I, Stage II, Stage III, or Stage IV Chronic Lymphocytic Leukemia | NCT00276809 | Chronic Lymphoc... | alemtuzumab filgrastim carmustine cyclophosphamid... cytarabine dexamethasone etoposide fludarabine pho... melphalan autologous bone... peripheral bloo... radiation thera... | 18 Years - 60 Years | German CLL Study Group | |
| Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma | NCT00278161 | Leukemia Lymphoma | Pegfilgrastim Rituximab Cyclophosphamid... | 18 Years - 70 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Early or Delayed Fludarabine and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia | NCT00513747 | Leukemia | rituximab fludarabine pho... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation | NCT00005641 | Chronic Myelopr... Graft Versus Ho... Leukemia Multiple Myelom... Myelodysplastic... | anti-thymocyte ... busulfan cyclophosphamid... cyclosporine leucovorin calc... methotrexate methylprednisol... allogeneic bone... in vitro-treate... radiation thera... | 15 Years - 60 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia | NCT01649791 | B-cell Chronic ... Chronic Lymphoc... Stage 0 Chronic... Stage I Chronic... Stage II Chroni... | lenalidomide laboratory biom... lymph node biop... bone marrow asp... pharmacological... flow cytometry | 18 Years - | Roswell Park Cancer Institute | |
| Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell Lymphocytosis | NCT02309515 | Monoclonal B-Ce... Stage 0 Chronic... Stage I Chronic... Stage I Small L... | Laboratory Biom... Lenalidomide Pneumococcal 13... | 18 Years - | Mayo Clinic | |
| Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia | NCT01269385 | B-cell Chronic ... Refractory Chro... Stage 0 Chronic... Stage I Chronic... Stage II Chroni... | alemtuzumab rituximab PGG beta-glucan flow cytometry laboratory biom... DNA analysis fluorescence in... polymerase chai... polymorphism an... mutation analys... | 18 Years - | Mayo Clinic | |
| FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia | NCT00769522 | Chronic Lymphoc... | Rituximab Bendamustine Cyclophosphamid... Fludarabine | 18 Years - | German CLL Study Group | |
| Theophylline in Treating Patients With In Situ, Stage I, or Stage II Chronic Lymphocytic Leukemia | NCT00003808 | Leukemia | theophylline | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT01024010 | Chronic Lymphoc... Stage 0 Chronic... Stage I Chronic... Stage I Small L... Stage II Chroni... Stage II Small ... Stage III Chron... Stage III Small... Stage IV Chroni... Stage IV Small ... | Cyclophosphamid... Laboratory Biom... Ofatumumab Pentostatin | 18 Years - | Mayo Clinic | |
| Fludarabine With or Without Cyclophosphamide in Treating Patients With Chronic Lymphocytic Leukemia | NCT00003764 | Leukemia | cyclophosphamid... fludarabine pho... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Alemtuzumab and Rituximab in Treating Patients With High-Risk, Early-Stage Chronic Lymphocytic Leukemia | NCT00436904 | Leukemia | Alemtuzumab Rituximab | 18 Years - | Mayo Clinic | |
| Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer | NCT00004061 | Leukemia Lymphoma Oral Complicati... | filgrastim palifermin cyclophosphamid... etoposide ifosfamide peripheral bloo... quality-of-life... radiation thera... | 18 Years - 65 Years | National Cancer Institute (NCI) | |
| Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer | NCT00004061 | Leukemia Lymphoma Oral Complicati... | filgrastim palifermin cyclophosphamid... etoposide ifosfamide peripheral bloo... quality-of-life... radiation thera... | 18 Years - 65 Years | National Cancer Institute (NCI) | |
| Fludarabine or Observation in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia | NCT00262782 | Chronic Lymphoc... | Fludarabine | 18 Years - 75 Years | German CLL Study Group | |
| Fludarabine and Darbepoetin Alfa in Treating Older Patients With Chronic Lymphocytic Leukemia | NCT00281892 | Chronic Lymphoc... Anemia | Fludarabine plu... Fludarabine mon... | - | German CLL Study Group | |
| FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia | NCT00769522 | Chronic Lymphoc... | Rituximab Bendamustine Cyclophosphamid... Fludarabine | 18 Years - | German CLL Study Group | |
| Cyclophosphamide and Total Body Irradiation in Treating Patients Who Are Undergoing an Autologous Peripheral Stem Cell Transplant For Chronic Lymphocytic Leukemia | NCT00275015 | Chronic Lymphoc... | filgrastim carmustine cyclophosphamid... cytarabine dexamethasone etoposide fludarabine pho... melphalan bone marrow abl... peripheral bloo... radiation thera... | 18 Years - 60 Years | German CLL Study Group | |
| Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia in Partial Remission or Complete Remission | NCT00458523 | Leukemia | alemtuzumab fluorescence in... mutation analys... flow cytometry | 18 Years - | National Cancer Institute (NCI) | |
| Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas | NCT02213913 | Adult Grade III... B-cell Chronic ... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Cutaneous B-cel... Extranodal Marg... Intraocular Lym... Nodal Marginal ... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Progressive Hai... Small Intestine... Splenic Margina... Stage 0 Chronic... Stage I Adult D... Stage I Adult D... Stage I Adult D... Stage I Adult H... Stage I Adult I... Stage I Chronic... Stage I Grade 1... Stage I Grade 2... Stage I Grade 3... Stage I Mantle ... Stage I Margina... Stage I Small L... Stage II Adult ... Stage II Chroni... Stage II Small ... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Chron... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Chroni... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Testicular Lymp... Untreated Hairy... Waldenström Mac... | lenalidomide etoposide prednisone vincristine sul... doxorubicin hyd... cyclophosphamid... rituximab quality-of-life... laboratory biom... | 18 Years - | University of Chicago | |
| Chemotherapy in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia | NCT00004218 | Leukemia | chlorambucil cyclophosphamid... doxorubicin hyd... fludarabine pho... prednisolone vincristine sul... | - | National Cancer Institute (NCI) | |
| Rituximab and GM-CSF in Treating Patients With Chronic Lymphocytic Leukemia | NCT00265915 | Leukemia | rituximab sargramostim | 15 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT01351896 | Ann Arbor Stage... Ann Arbor Stage... Chronic Lymphoc... Chronic Lymphoc... Small Lymphocyt... Small Lymphocyt... Stage 0 Chronic... Stage I Chronic... Stage II Chroni... | Laboratory Biom... Lenalidomide Pharmacological... Pneumococcal Po... | 18 Years - 79 Years | National Cancer Institute (NCI) | |
| Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT01351896 | Ann Arbor Stage... Ann Arbor Stage... Chronic Lymphoc... Chronic Lymphoc... Small Lymphocyt... Small Lymphocyt... Stage 0 Chronic... Stage I Chronic... Stage II Chroni... | Laboratory Biom... Lenalidomide Pharmacological... Pneumococcal Po... | 18 Years - 79 Years | National Cancer Institute (NCI) | |
| Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer | NCT00004132 | Drug/Agent Toxi... Leukemia Lymphoma Multiple Myelom... Oral Complicati... Radiation Toxic... | filgrastim palifermin cyclophosphamid... etoposide ifosfamide quality-of-life... radiation thera... | 12 Years - 65 Years | National Cancer Institute (NCI) | |
| Green Tea Extract in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia | NCT00262743 | Leukemia | Polyphenon E | 18 Years - | Mayo Clinic | |
| Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell Lymphocytosis | NCT02309515 | Monoclonal B-Ce... Stage 0 Chronic... Stage I Chronic... Stage I Small L... | Laboratory Biom... Lenalidomide Pneumococcal 13... | 18 Years - | Mayo Clinic | |
| Green Tea Extract in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia | NCT00262743 | Leukemia | Polyphenon E | 18 Years - | Mayo Clinic | |
| Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia | NCT00563290 | Recurrent Skin ... Squamous Cell C... Stage 0 Chronic... Stage I Chronic... | dasatinib laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia | NCT00563290 | Recurrent Skin ... Squamous Cell C... Stage 0 Chronic... Stage I Chronic... | dasatinib laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia | NCT00562328 | Leukemia | Alemtuzumab Rituximab Sargramostim | 18 Years - 120 Years | Mayo Clinic |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
